Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase 纬 Inhibitors

详细信息    查看全文

• 作者：James W. Leahy ; Chris A. Buhr ; Henry W. B. Johnson ; Byung Gyu Kim ; TaeGon Baik ; Jonah Cannoy ; Timothy P. Forsyth ; Joon Won Jeong ; Matthew S. Lee ; Sunghoon Ma ; Kevin Noson ; Longcheng Wang ; Matthew Williams ; John M. Nuss ; Eric Brooks ; Paul Foster ; Leanne Goon ; Nathan Heald ; Charles Holst ; Christopher Jaeger ; Scott Lam ; Julie Lougheed ; Lam Nguyen ; Arthur Plonowski ; Joanne Song ; Thomas Stout ; Xiang Wu ; Michael F. Yakes ; Peiwen Yu ; Wentao Zhang ; Peter Lamb ; Olivia Raeber
• 刊名：Journal of Medicinal Chemistry
• 出版年：2012
• 出版时间：June 14, 2012
• 年：2012
• 卷：55
• 期：11
• 页码：5467-5482
• 全文大小：645K
• 年卷期：v.55,no.11(June 14, 2012)
• ISSN：1520-4804

文摘

The phosphoinositide 3-kinases (PI3Ks) have been linked to an extraordinarily diversified group of cellular functions making these enzymes compelling targets for the treatment of disease. A large body of evidence has linked PI3K纬 to the modulation of autoimmune and inflammatory processes making it an intriguing target for drug discovery. Our high-throughput screening (HTS) campaign revealed two hits that were nominated for further optimization studies. The in vitro activity of the first HTS hit, designated as the sulfonylpiperazine scaffold, was optimized utilizing structure-based design. However, nonoptimal pharmacokinetic properties precluded this series from further studies. An overlay of the X-ray structures of the sulfonylpiperazine scaffold and the second HTS hit within their complexes with PI3K纬 revealed a high degree of overlap. This feature was utilized to design a series of hybrid analogues including advanced leads such as 31 with desirable potency, selectivity, and oral bioavailability.